Shenzhen New Industries Biomedical Engineering Co.,Ltd. (300832.SZ) has released its semi-annual report for the first half of the year, revealing that the company achieved operating revenue of 2.42 billion yuan, representing a year-on-year increase of 10.78%. Net profit attributable to shareholders of the parent company reached 868 million yuan, up 12.53% compared to the same period last year.
Excluding non-recurring gains and losses, net profit attributable to shareholders stood at 825 million yuan, a rise of 13.60% year-on-year. Basic earnings per share were 1.1057 yuan. During the reporting period, the company's gross margin structure exhibited a strategic divergence. The gross margin for the instrument product line was 22.08%, a decrease of 4.08 percentage points year-on-year.
To mitigate the impact of multiple policies such as domestic centralized procurement, the company implemented several measures to ensure reagent gross margin stability. These measures included increasing the promotion of high-value-added reagent projects, optimizing the supply chain, enhancing automation and large-scale production, and boosting the proportion of self-produced reagent raw materials. Notably, the small-molecule sandwich method reagent project generated revenue of 157.71 million yuan, a substantial 84.79% year-on-year increase, reflecting the project's strong market recognition.
During the period, the company's reagent gross margin remained relatively stable, benefiting from the increased share of overseas reagent revenue. As the proportion of reagent revenue in the main business income rose, the comprehensive gross margin for the main business stood at 71.09%, an increase of 2.45 percentage points year-on-year.
Comments